ArticleThe Journal of experimental medicine2003
CCR5 expression influences the progression of human breast cancer in a p53-dependent manner.
Article in The Journal of experimental medicine, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 139 citations in OpenAlex.
- CCR5 Receptor Occupancy Analysis Reveals Increased Peripheral Blood CCR5+CD4+ T Cells Following Treatment With the Anti-CCR5 Antibody Leronlimab.Frontiers in immunology · 2021Trial
- Circulating chemokines and leukocytes and their impact on breast cancer prognosis.Discover oncology · 2025Article
- Targeting Hdm2 and Hdm4 in Anticancer Drug Discovery: Implications for Checkpoint Inhibitor Immunotherapy.Cells · 2024Review
- Carrying SNP rs17506395 (T > G) inOpen life sciences · 2024Article
- Single-molecule and super-resolved imaging deciphers membrane behavior of onco-immunogenic CCR5.iScience · 2022Article
- Naming the Barriers between Anti-CCR5 Therapy, Breast Cancer and Its Microenvironment.International journal of molecular sciences · 2022Review
- Tumor Cell-Autonomous Pro-Metastatic Activities of PD-L1 in Human Breast Cancer Are Mediated by PD-L1-S283 and Chemokine Axes.Cancers · 2022Article
- CCL5/CCR5 axis in human diseases and related treatments.Genes & diseases · 2022Review
- A seven-gene signature and the C-C motif chemokine receptor family genes are the sarcoma-related immune genes.Bioengineered · 2021Article
- Macrophage-derived cytokines in pneumonia: Linking cellular immunology and genetics.Cytokine & growth factor reviews · 2021Review
- Evaluating the Association betweenIranian journal of public health · 2021Article
- Stromal CCL5 Promotes Breast Cancer Progression by Interacting with CCR3 in Tumor Cells.International journal of molecular sciences · 2021Article
- Molecular and Cellular Factors Associated with Racial Disparity in Breast Cancer.International journal of molecular sciences · 2020Review
- Role of Chemokines in the Biology of Cholangiocarcinoma.Cancers · 2020Review
- CCR5 deficiency impairs CD4The EMBO journal · 2020Article
- Clinical significance and prospective molecular mechanism of C‑C motif chemokine receptors in patients with early‑stage pancreatic ductal adenocarcinoma after pancreaticoduodenectomy.Oncology reports · 2019Article
- Association analysis and allelic distribution of deletion in CC chemokine receptor 5 gene (CCR5Δ32) among breast cancer patients of Pakistan.Molecular biology reports · 2019Article
- CC chemokines are differentially expressed in Breast Cancer and are associated with disparity in overall survival.Scientific reports · 2019Article
- CCR5 blockage by maraviroc: a potential therapeutic option for metastatic breast cancer.Cellular oncology (Dordrecht, Netherlands) · 2019Article
- Integrated Transcriptome and Pathway Analyses Revealed Multiple Activated Pathways in Breast Cancer.Frontiers in oncology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chemokines are implicated in tumor pathogenesis, although it is unclear whether they affect human cancer progression positively or negatively. We found that activation of the chemokine receptor CCR5 regulates p53 transcriptional activity in breast cancer cells through pertussis toxin-, JAK2-, and p38 mitogen-activated protein kinase-dependent mechanisms. CCR5 blockade significantly enhanced proliferation of xenografts from tumor cells bearing wild-type p53, but did not affect proliferation of tumor xenografts bearing a p53 mutation. In parallel, data obtained in a primary breast cancer clinical series showed that disease-free survival was shorter in individuals bearing the CCR5Delta32 allele than in CCR5 wild-type patients, but only for those whose tumors expressed wild-type p53. These findings suggest that CCR5 activity influences human breast cancer progression in a p53-dependent manner.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.